CoChat

Effect of perindopril or leucine on physical performance in older people with sarcopenia: the LACE randomized controlled trial

Open access
The LACE study group, Achison, Marcus, Adamson, Simon, Akpan, Asangaedem, Aspray, Terry, Avenell, Alison, Band, Margaret M., Bashir, Tufail, Burton, Louise A., Cvoro, Vera, Donnan, Peter T., Duncan, Gordon W., George, Jacob, Gordon, Adam L., Gregson, Celia L., Hapca, Adrian, Henderson, Emily, Hume, Cheryl, Jackson, Thomas A., Kemp, Paul, Kerr, Simon, Kilgour, Alixe, Lyell, Veronica, Masud, Tahir, McKenzie, Andrew, McKenzie, Emma, Patel, Harnish, Pilvinyte, Kristina, Roberts, Helen C., Rossios, Christos, Sayer, Avan A., Smith, Karen T., Soiza, Roy L., Steves, Claire J., Struthers, Allan D., Sumukadas, Deepa, Tiwari, Divya, Whitney, Julie, Witham, Miles D. · 2022 · Journal of Cachexia, Sarcopenia and Muscle
Cited by 51

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Background: This trial aimed to determine the efficacy of leucine and/or perindopril in improving physical function in older people with sarcopenia. Methods: Placebo‐controlled, parallel group, double‐blind, randomized two‐by‐two factorial trial. We recruited adults aged ≥ 70 years with sarcopenia, defined as low gait speed (<0.8 m/s on 4 m walk) and/or low handgrip strength (women < 20 kg, men < 30 kg) plus low muscle mass (using sex and body mass index category‐specific thresholds derived from normative UK BioBank data) from 14 UK centres. Eligible participants were randomized to perindopril 4 mg or placebo, and to oral leucine powder 2.5 g or placebo thrice daily. The primary outcome was the between‐group difference in the short physical performance battery (SPPB) score over 12‐month follow‐up by repeated‐measures mixed models. Results were combined with existing systematic reviews using random‐effects meta‐analysis to derive summary estimates of treatment efficacy. Results: We screened 320 people and randomized 145 participants compared with an original target of 440 participants. For perindopril [n = 73, mean age 79 (SD 6), female sex 39 (53%), mean SPPB 7.1 (SD 2.3)] versus no perindopril [n = 72, mean age 79 (SD 6), female sex 39 (54%), mean SPPB 6.9 (SD 2.4)], median adherence to perindopril was lower (76% vs. 96%; P < 0.001). Perindopril did not improve the primary outcome [adjusted treatment effect −0.1 points (95%CI −1.2 to 1.0), P = 0.89]. No significant treatment benefit was seen for any secondary outcome including muscle mass [adjusted treatment effect −0.4 kg (95%CI −1.1 to 0.3), P = 0.27]. More adverse events occurred in the perindopril group (218 vs. 165), but falls rates were similar. For leucine [n = 72, mean age 78 (SD 6), female sex 38 (53%), mean SPPB 7.0 (SD 2.1)] versus no leucine [n = 72, mean age 79 (SD 6), female sex 40 (55%), mean SPPB 7.0 (SD 2.5)], median adherence was the same in both groups (76% vs. 76%; P = 0.99). Leucine did not improve the primary outcome [adjusted treatment effect 0.1 point (95%CI −1.0 to 1.1), P = 0.90]. No significant treatment benefit was seen for any secondary outcome including muscle mass [adjusted treatment effect −0.3 kg (95%CI −1.0 to 0.4), P = 0.47]. Meta‐analysis of angiotensin converting enzyme inhibitor/angiotensin receptor blocker trials showed no clinically important treatment effect for the SPPB [between‐group difference −0.1 points (95%CI −0.4 to 0.2)]. Conclusions: Neither perindopril nor leucine improved physical performance or muscle mass in this trial; meta‐analysis did not find evidence of efficacy of either ACE inhibitors or leucine as treatments to improve physical performance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jcsm.12934

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 51

Metadata

Authors
The LACE study group, Achison, M., Adamson, S., Akpan, A., Aspray, T., Avenell, A., Band, M. M., Bashir, T., Burton, L. A., Cvoro, V., Donnan, P. T., Duncan, G. W., George, J., Gordon, A. L., Gregson, C. L., Hapca, A., Henderson, E., Hume, C., Jackson, T. A., Kemp, P., Kerr, S., Kilgour, A., Lyell, V., Masud, T., McKenzie, A., McKenzie, E., Patel, H., Pilvinyte, K., Roberts, H. C., Rossios, C., Sayer, A. A., Smith, K. T., Soiza, R. L., Steves, C. J., Struthers, A. D., Sumukadas, D., Tiwari, D., Whitney, J., & Witham, M. D.
Venue
Journal of Cachexia, Sarcopenia and Muscle
Publisher
Wiley
Published
2022-02-16
Volume
13
Issue
2
Pages
858-871
ISSN
  • 2190-5991 (ISSN-L)
  • 2190-6009
OpenAlex
W4213065184
Cited by
51
References
15
FWCI
5.26
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.